GHK-Cu: The Definitive Guide

What is GHK-Cu?

GHK-Cu is a very small peptide, just three amino acids long, bound to one copper atom. It is best known as a skin-care ingredient, and some people also inject it for skin, hair and recovery goals.

The letters stand for its three building blocks: glycine (G), histidine (H) and lysine (K), with Cu, the chemical symbol for copper. In 1973 researchers found a factor in human blood that helped liver cells survive in a dish; in 1977 they identified it as GHK, and later work showed that it grabs copper tightly. Ingredient labels call the copper form "copper tripeptide-1", and its drug name is prezatide copper. In the 1990s a company called ProCyte tested it as a wound gel named Iamin. [1], [2], [3], [4], [5]

Three versions share the name, and they are not interchangeable: GHK without copper, GHK-Cu with one peptide per copper atom, and prezatide copper acetate, the wound-gel form with two peptides per copper atom. Some similar-sounding ingredients, such as AHK-Cu and palmitoyl tripeptide-1, are different molecules altogether. [6], [4], [5], [7]

Doserly

Three substances share the GHK name

GHK (no copper)

Glycine-histidine-lysine alone. Formula C₁₄H₂₄N₆O₄, 340.38 g/mol. Occurs naturally in human blood. Used in many cell and gene-data studies.

0% copper

GHK-Cu (copper tripeptide-1)

One peptide holding one copper atom. Formula C₁₄H₂₂N₆O₄Cu, 401.91 g/mol. Skin-care ingredient and injectable research vials.

about 16% copper (2 mg carries about 0.32 mg)

Prezatide copper acetate (Iamin)

Two peptides sharing one copper atom. 862.39 g/mol. The form in the 1990s wound gels.

about 7% copper

Not GHK-Cu

AHK-Cu (copper tripeptide-3) A different copper peptide; used in the often-cited hair-follicle lab study.

Palmitoyl tripeptide-1 GHK with a fatty-acid tail and no copper (in Matrixyl 3000).

Chemistry from FDA substance records; copper shares are arithmetic from those formula weights

How much copper a product carries, and which form a study used, changes what a result means.

The key word is investigational: researchers have not established what injected GHK-Cu does in people or what its risks are. As a skin-care ingredient it has a long history of use at low strengths. As a subcutaneous injection, the way people use it today, we found no human studies at all. This guide explains the protocols people describe, what the skin and wound research actually found, and what remains unknown. [8], [9], [10]

Typical GHK-Cu Protocols

The most common protocol in the reviewed sources is 1–2 mg once daily by subcutaneous injection for about 30 days to 6 weeks, followed by a break of about 2–4 weeks. [12], [14], [15], [16], [17], [18], [53]

Titration Changing the amount in steps

When sources build up gradually, the usual approach starts at 1 mg a day and moves up to 2 mg. One clinic schedule doubles the amount halfway through a 30-day course (1 mg for days 1–15, then 2 mg for days 16–30); another steps from 1 mg to 1.5 mg to 2 mg at four-week intervals, five days a week. Many sources skip titration and start at the full amount. [18], [19], [12]

Breaks and cycles

Sources describe a break of 2–4 weeks after a 4–8-week course, 14 days off after 30 days on, or an equally long break after a 30-day course. One clinician handout repeats 6-week courses three or four times a year. [11], [12], [18], [14]

Read the units: 1 mg equals 1,000 mcg. Amounts refer to GHK-Cu itself, not to the total weight of a blend such as GLOW or KLOW, and not to the copper inside it. About 16% of GHK-Cu's weight is copper, so 2 mg of GHK-Cu carries about 0.32 mg of copper. [4]

Each row is a complete schedule as its source published it, so the amount and the course length belong together. Low, mid and high are alternatives, not steps to move through. These schedules come from protocol websites, clinic handouts and a pharmacy leaflet rather than clinical trials; we found no human study of subcutaneous GHK-Cu. The cited references give the full details. [10], [20]

Before relying on any row: none of these amounts has been tested for safety in people, and FDA flags a possible risk of immune reactions with injectable GHK-Cu. [10], [9] Injectable products have been recalled because their sterility could not be assured, and painful injection-site reactions are the most common complaint in community reports. [104], [82], [46], [74] Each 2 mg carries about 0.32 mg of copper, which matters for anyone with Wilson disease and adds to any copper taken by mouth. [4], [88] Mixing mistakes happen: one person injected 66 times the intended amount after a mixing error, so work out syringe units with the reconstitution calculator rather than copying them. [145] It has not been studied in pregnancy, breastfeeding or anyone under 18. Full risks ↓

Where protocols differ: dose steps, breaks, blends and units ↓

What is GHK-Cu commonly used for?

Most people come to GHK-Cu through skin care: a copper-peptide serum for fine lines, texture or a tired-looking complexion. Others inject it hoping for a whole-body version of the same effect, or take it inside the GLOW and KLOW blends for joint pain and injury recovery.

The research behind these uses is thin and uneven. Small studies of creams and gels exist for skin aging, eyebrows and wounds. For subcutaneous injections we found no human research at all, so what follows describes the hopes and the reports, not established benefits. [10], [26]

Skin aging, texture and "glow"

This is the main reason people use GHK-Cu. The hoped-for results are firmer, smoother and more even skin, softer fine lines and a healthier look. In the small skin studies, a GHK-Cu serum used twice daily for 8 weeks reduced measured wrinkle volume more than an inactive serum in one company-connected trial (the inactive serum also lacked the delivery system that carried the GHK-Cu), while a 12-week study after laser resurfacing found no objective difference at all. [27], [26]

People who inject it describe similar goals, often within the first two months. Their accounts usually include other changes at the same time, such as weight-loss medicines, retinoids or other peptides, which makes GHK-Cu's own contribution hard to judge. The experience section follows several accounts. [28], [29], [119]

Hair, eyebrows and lashes

Hair growth is the second big interest. The only controlled human study of GHK-Cu and hair was on eyebrows: after 12 weeks of a 2% serum, treated brows had slightly more hairs than brows given an inactive serum (about 31 versus 29), a difference just past the usual threshold for statistical significance. No controlled study has tested GHK-Cu alone for scalp hair loss. The laboratory hair-follicle paper often quoted for hair used AHK-Cu, a different copper peptide. [30], [7], [10]

Wounds and scars

GHK-Cu's medical history is in wound care. In the 1990s its developer tested a gel on diabetic foot ulcers and a cream on leg ulcers. The results were mixed and a large trial failed, which the human research section explains. Scar claims rest on a small uncontrolled study of a gel that combined copper tripeptide-1 with three other active ingredients. [31], [32], [33], [34]

Joint pain and injury recovery

Much of the joint and injury interest involves blends rather than GHK-Cu alone: GLOW combines GHK-Cu with BPC-157 and TB-500, and KLOW adds KPV. A person who feels better on a four-peptide blend cannot tell which ingredient helped. For GHK-Cu itself there is no human joint or tendon study; in rats, injections into the knee after ligament surgery made the knee slightly less loose for a time, with no lasting difference. [35], [36], [37]

Other uses you may come across

Websites also promote GHK-Cu for lungs, the gut, the brain, sleep and "longevity", often citing a claim that it resets about 4,000 genes. Those claims come from mouse experiments and from a computer analysis of cancer cells treated with GHK without copper, not from studies in people. [38], [39], [40], [41]

See the human study results or explore the supporting animal research.

Where do GHK-Cu protocols differ?

The recurring 1–2 mg daily amount is easy to summarize. The details around it are not: sources disagree about how often to inject, whether to build up gradually, how long to continue and whether breaks matter. Here is what those differences mean when reading a protocol.

Is the number for one dose or the whole day?

For most GHK-Cu protocols the two are the same, because the injection is once a day. The difference appears with less frequent schedules: 2 mg three times a week adds up to 6 mg a week, while 2 mg daily is 14 mg a week. Always check how many injections a stated amount covers. [42], [12]

Two other numbers get mixed up with the dose. A blend's weight is not its GHK-Cu content, and GHK-Cu's weight is not its copper content (about 16% of it is copper). [4], [36]

Once daily or a few times a week?

Both appear. Daily injection is the most common pattern, and some sources use five days on and two days off each week. Others describe 1–2.5 mg two to three times a week for 6–8 weeks, 1–5 mg two to three times a week, or a schedule that starts every other day and moves to three times a week. No study has compared these schedules. [19], [43], [44], [25], [42]

Do sources start low, or start at the full amount?

Some start at 1 mg and move to 2 mg halfway through a 30-day course. Another starts at 1 mg and steps up by 0.5 mg every four weeks. A post-surgery page uses much smaller amounts, 200–300 mcg a day. Many sources start at the full amount from day one. [18], [19], [45], [12]

A gradual start is often explained as a way to reduce injection-site stinging, which community accounts describe as the main problem with GHK-Cu. That is a practical rationale, not a tested one. There is no evidence that a lack of improvement at one amount means a higher amount will work. [46], [47]

How many weeks, and what happens between cycles?

A course is the period of repeated use; a cycle is that course plus a planned break. Published courses range from 30 days to about 16 weeks, with breaks from 2 weeks to 2 months. One page criticizes the widely repeated schedule of 1.7 mg daily, 8 weeks on and 8 weeks off, as a community convention with no evidence behind it. [12], [18], [42], [15], [19], [43], [20]

The reasons given for breaks vary: to prevent copper from building up, to restore receptor sensitivity, or simply because long-term effects are unknown. None is backed by data. No GHK-Cu receptor has been identified, no study has measured copper build-up after repeated injections, and one clinic page says plainly that cycling "is more common in practice but not based on evidence". In community education groups, educators are split between planned breaks and continuous use for many months. [15], [42], [18], [48], [49], [62], [53], [50], [25]

Where do the sources disagree most?

• Daily amount: most pages sit at 1–2 mg a day, but the published range runs from 100 mcg to 5 mg per injection. A higher reported amount is not a verified safe ceiling. [45], [11], [24], [25]
• Frequency: daily, five days a week and two or three times a week all appear. [19], [44]
• Course and breaks: 30 days to about 16 weeks on; 2 weeks to 2 months off; or no break. [12], [42], [15], [19], [13]
• Community practice: people in community education groups most often describe 2 mg a day. Some members run 4–10 mg a day for months, far beyond any published protocol, and one educator lesson paired 10 mg a day with an oral copper supplement. Those are reports of practice, not tested doses.

Why do so many sources say 1.7 mg?

It matches simple vial arithmetic, not a study: a 50 mg vial divided into 30 daily doses gives about 1.67 mg per dose. The same arithmetic produces the GHK-Cu amount in the common GLOW and KLOW blend vials, which usually contain 50 mg of GHK-Cu. [20], [35], [36]

What about the GLOW and KLOW blends?

GLOW usually combines 50 mg of GHK-Cu with 10 mg each of BPC-157 and TB-500 in one vial; KLOW adds 10 mg of KPV. Because the ratio is fixed, choosing the GHK-Cu amount also fixes the others. Blend schedules need their own table:

The blend's total amount is not its GHK-Cu amount: 2.33 mg of GLOW contains about 1.67 mg of GHK-Cu. Blend vials are sold in other ratios too, and one protocol site describes GLOW as containing full-length thymosin beta-4 rather than TB-500, so the component amounts and even the ingredients depend on the label. No study has tested these blends in people. Read the Doserly guides to GLOW and KLOW for the partner peptides. [35], [22], [51]

How do milligrams convert to syringe units?

Many people measure injections in "units" on an insulin syringe. A U-100 syringe holds 100 units per millilitre, so units measure volume, not an amount of GHK-Cu. How much GHK-Cu each unit holds depends on how much liquid was added to the vial.

For example, 50 mg mixed into 5 mL gives 10 mg per mL, or 0.1 mg per unit, so 2 mg is 20 units. The same 50 mg mixed into 3 mL makes 2 mg about 12 units. That is why a number of units copied from someone else's protocol can be wrong. Doserly's reconstitution calculator works this out for any vial and shows each step. [43]

What happens when you stop GHK-Cu?

We found no study of it. No human or animal study we found looked for withdrawal effects or a rebound. The 1994 wound-gel trial kept measuring ulcers for six weeks after treatment ended but did not report what changed after stopping, and the skin and eyebrow trials stopped measuring at the last treatment visit. That is an absence of data, not proof that nothing happens. [31], [30], [27], [10]

• Reactions usually settled. In public forums, injection-site reactions and whole-body symptoms were usually described as fading within days of stopping. One person said head pressure and a feeling of unreality continued five days after stopping; another described a site that stayed reactive for months. [58], [59], [60]
• Some benefits faded. One person said facial redness slowly returned during a month off after three months of daily injections. Another said red, dry skin returned about three weeks after finishing a KLOW course, a blend that makes the cause impossible to separate. [28], [61]
• Claims without data. Websites say that levels return to baseline within 7–10 days, that benefits drift 60–80% back toward baseline, and that breaks restore receptor sensitivity. None of these claims cites a measurement. [62], [63], [49]

No taper is described in the sources, and community education groups say none is needed. The breaks that protocols describe are a source convention, not a response to known withdrawal effects.

Do skin creams and injections of GHK-Cu behave the same way?

No, and the difference matters more for GHK-Cu than for most peptides, because nearly all the human research used one route and most self-experimenters use another. A topical product (applied to the skin) has to cross the skin's outer barrier. A subcutaneous injection places the peptide in the fatty layer under the skin, where it can reach the bloodstream. These are different exposures, not stronger and weaker versions of the same thing.

Doserly

What has been tested depends on the route

Topical (cream, gel, serum)

limited evidence

How people use it

Skin care; 1990s wound gels

Human studies

Small trials: wound creams and gels (1992, 1994, failed 511-person Phase III), skin and eyebrow serums

What is measured

Skin permeation in donor skin: about 2% of applied copper crossed in 48 h; intact peptide not measured

Subcutaneous injection

no human data

How people use it

Most self-experimenters; 1–2 mg daily on protocol sites

Human studies

None

What is measured

No human blood levels or half-life

Intradermal (skin procedures)

no human data

How people use it

Cosmetic mesotherapy, 0.5–1 mg per session

Human studies

None

What is measured

Not measured

Nasal spray or capsule

no human data

How people use it

Sold by some vendors

Human studies

None (nasal tested only in mice)

What is measured

Not measured

Skin permeation was measured in donor skin in the laboratory, not in living people.

Creams, gels and serums have small human studies; subcutaneous and intradermal injections, nasal sprays and capsules have none.

How much gets through the skin has been measured only in skin removed from donors. With a copper-peptide solution, about 2% of the applied copper crossed the skin over 48 hours; the intact peptide was not measured. When the skin was first pierced with tiny needles, measurable amounts of the peptide itself crossed. A 2025 laboratory study found GHK-Cu held in the skin but none in the fluid beneath it. Copper crossing the skin is not proof that intact GHK-Cu reaches the body. [64], [65], [66]

For injections, we found no measurements in people: not how much reaches the blood, how long it stays or what happens to its copper. In test-tube studies, copper-bound GHK forms combined complexes with albumin, the main protein in blood, so injected GHK-Cu may not stay in its original form. [67], [10]

How long does GHK-Cu last in the body?

Nobody knows for people. Half-life is the time it takes for the level in the blood to fall by half. It has never been measured for GHK-Cu in humans by any route. In rats given GHK without copper into a vein (intravenous), GHK was quickly broken down into a two-amino-acid fragment that was also cleared quickly; the study gives no half-life number. [68]

Website figures such as a half-life of about 2–4 hours in rodents or peak levels about 30 minutes after injection have no published source that we could find. A half-life, even when measured, would not tell you how long an effect on skin lasts. [69]

What strengths do skin products and studies use?

The cosmetic safety panel found copper tripeptide-1 and related peptides safe "in the present practices of use and concentration in cosmetics". Its industry survey did not report how strong the copper tripeptide-1 products were; the highest strength it found, 0.002%, was for a different peptide. So the panel's conclusion does not show that 1–2% serums are safe, and it says nothing about injection. [8], [31], [33], [30], [70], [71]

Are nasal sprays, capsules and skin injections the same?

No study in people has tested any of them. Sellers offer nasal sprays (one lists its amounts with a milligram-for-microgram error), capsules that combine 2 mg of GHK-Cu with BPC-157 and carnosine, and intradermal injections into the skin during cosmetic procedures, at 0.5–1 mg per session every 2–4 weeks. Nasal delivery has been tested only in mice. [48], [72], [73], [41]

Should GHK-Cu be injected near the area you want to change?

No study has compared injecting near the face or scalp with injecting elsewhere. Protocol sources and community accounts mostly use the abdomen, thighs or buttocks and expect a whole-body effect. Where to inject matters for comfort: community accounts most often describe the abdomen as the most painful site and the upper buttock as the least. [15], [74], [46]

How should GHK-Cu be stored, and how long does it last?

We found no published stability study of injectable GHK-Cu, so storage advice comes from suppliers and protocol pages, not from a tested medicine label. [10], [75]

• Powder, before mixing. GHK-Cu is usually sold as a freeze-dried powder. One research-chemical supplier states that its solid GHK-Cu is stable for at least four years at −20 °C. [76]
• After mixing. The same supplier does not recommend keeping a water-based solution for more than one day. Peptide sellers and protocol pages instead give 2 weeks to 60 days in a fridge (2–8 °C), most often 28–30 days, without showing test data; one seller calls 2–4 weeks general peptide practice "rather than a validated expiry". One vial label reported in a forum said to discard it 28 days after the first puncture, while the seller said one vial lasts eight weeks. [76], [77], [78], [79], [80]
• What the chemistry shows. In a laboratory stress test, GHK-Cu stayed stable in water and in mildly acidic to neutral solutions (pH 4.5–7.4) for at least two weeks at 60 °C. It broke down faster under alkaline and oxidizing conditions. [75]

The blue color is not a quality test. Blue comes from the copper, but in the developer's own patent a concentrated solution stayed "deep blue" while it formed a heavy sediment. Color cannot show identity, strength or sterility. Sterility is its own issue: FDA's recall records include injectable GHK-Cu products recalled because sterility could not be assured. This guide does not cover mixing or injection technique; the Academy note below covers practical handling. [81], [82]

What do we actually know about GHK-Cu in people?

Almost every human study of GHK-Cu applied it to the skin or to a wound. Most are small, short and connected to a company selling the product. A 2026 systematic review of GHK-Cu used alone for cosmetic and skin purposes found 20 studies up to March 2026, of which 18 were preclinical (cell or animal) and only 2 were randomized trials in people. [10]

Feeling or looking better after a treatment is real to the person experiencing it. Working out why is a separate task: skin changes with seasons, sun, weight, other products and time, and people tend to expect results. Controlled studies help separate those effects from the treatment itself.

What did the human studies find?

Two newer studies tested products that mixed GHK-Cu with other active ingredients and had no comparison group. In 2026, 30 adults with sensitive skin used a cream with 0.2% GHK-Cu and a ferment extract twice daily for 56 days; in 2025, a scar gel combined copper tripeptide-1 with three other active ingredients. Both involved authors from the companies behind the products, and neither can show what GHK-Cu itself did. [85], [34]

The developer also tested the wound-gel form (two peptides per copper atom) as a nightly enema for ulcerative colitis, a bowel disease. A 1996 trade report described a placebo-controlled trial in 51 people that found about twice the reduction in disease activity with the higher strength as with placebo. The results were never published in full, so the size of the effect and the side effects cannot be checked. [144]

The wound-gel story shows why one positive trial is not enough. The 1994 subgroup results looked strong, the follow-up trial with 511 people failed, and the product later reached the market only as a wound dressing cleared as a medical device, not as a drug. [31], [32], [86]

Doserly

The wound-gel trials, in order

1992 · Leg ulcer trial

0.4% cream no better than an inactive cream (93 people).

1994 · Diabetic foot ulcer trial

181 people. In plantar ulcers treated straight away, median area closure 98.5% vs 60.8%; later-start groups did not benefit.

1994 · Phase III trial

511 people at 30 centers. Missed both main goals: about one-third of ulcers fully closed in every group, including placebo. Never published in a journal.

1996 · Device clearance

Iamin gel cleared as a wound dressing (510(k)), not approved as a drug.

Phase III results come from 1994 trade-press reports; the trial was never published in a journal.

One promising subgroup result was followed by a larger trial that failed; the gel was later cleared only as a wound dressing.

What would a useful improvement look like?

Skin studies measure different things: wrinkle depth from photographs or scans, skin samples under a microscope, hair counts, or how people rate their own skin. These can disagree. In the laser study, people felt their skin looked better even though measurements found no difference. [26]

For a person, a useful improvement is one that shows in consistent photographs under the same lighting, lasts after the first few weeks and does not come with new problems. The more helpful stories say what else changed at the same time, such as weight, new products or sun. [28]

Has anyone tested injected GHK-Cu in people?

Not in the way people inject it today. The only human injection study we found was a small 1992 pilot, published in a wound-care journal, in which the developer injected a sterile GHK-Cu solution directly into diabetic ulcers. We could not obtain the original report and know it from its description in a 1994 paper. We found no human study of subcutaneous, intramuscular or intravenous GHK-Cu, and no human blood-level data by any route. A 2026 clinical teaching report describes one accidental 132 mg injection, covered in the safety section. A 2026 registry entry for a topical gel comes from a sponsor whose sibling records describe themselves as fictional. [31], [145], [23], [56], [10]

How might GHK-Cu work?

Most of what is known about how GHK-Cu might work comes from cells in dishes and from animals. The main ideas are that it carries copper into cells, nudges fibroblasts (the cells that make collagen) to make more supporting tissue, and changes how damaged tissue is broken down and rebuilt.

Carrying copper

Copper is an essential nutrient. The body uses it in enzymes, including ones needed to build connective tissue. GHK binds copper very tightly, about as tightly as the copper-carrying site on albumin, the main protein in blood, and early experiments suggested it helps cells take copper up. Researchers have proposed that this copper delivery explains many of its effects, but that has not been shown in people, and extra copper does not help processes that already have enough. [3], [94], [87], [88]

Signals to collagen-making cells

In cultured human fibroblasts, GHK-Cu increased collagen production starting at extremely low concentrations, with the largest effect at about one billionth of a mole per litre. That is a concentration in a dish, not a dose for a person. In rats, GHK-Cu (in a form with two peptides per copper atom) injected into small wound chambers implanted in the body increased the amount of new connective tissue that built up inside them. [89], [90]

Breaking down and rebuilding tissue

Healing involves clearing damaged tissue as well as building new tissue. In rat wound chambers, GHK-Cu changed the activity of matrix metalloproteinases, enzymes that break down collagen. That fits the idea of "remodeling", but these are markers in animal tissue, not proof of better healing or younger-looking skin. [91]

Blood vessels and the cancer question

In a rabbit eye test, copper-bound GHK triggered new blood-vessel growth (angiogenesis) while GHK without copper did not. New blood vessels help wounds heal, and tumors also depend on them. [92]

Do the "4,000 genes" claims hold up?

Not as they are usually told. The figure comes from a computer analysis of public data in which GHK without copper was applied to prostate and breast cancer cells. About 4,200 of roughly 13,400 genes changed by at least half. That describes cancer cells in a dish, not people, and says nothing about whether those changes help. [38] An earlier colon-cancer study had searched the same database and flagged GHK as a compound whose effect ran opposite to a gene pattern linked to cancer spread. That was also a computer comparison; no one in it received GHK. [93]

Do blood levels of GHK fall with age?

That is often claimed, but we could not find the study behind it. The developer's reviews state that blood GHK falls from about 200 ng/mL at age 20 to 80 ng/mL at 60, without an age study that shows the measurements. Recent measurements in small groups of healthy adults found about 105–133 ng/mL. Some websites print the figure a thousand times too high, in micrograms. [94], [95], [96], [44]

The mixed picture matters as much as the positive findings. Some animal wound studies found no benefit or slower skin reorganization (one used a "copper peptide" its authors never identified), and a rat knee study found only a temporary change. [97], [98], [99], [37]

What are the risks and unanswered questions?

Is GHK-Cu safe?

On the skin at cosmetic strengths, the available evidence is reassuring; as a subcutaneous injection, its safety has not been studied in people. The small skin trials reported few reactions, and a cosmetic safety panel found it safe as used in cosmetics. For injections, FDA says there are limited human data to inform safety and has specifically flagged the risk of immune reactions. [8], [30], [9]

The closest thing to human injection safety data is a single case. A 2026 Canadian clinical teaching report describes a woman who injected 132 mg, 66 times her intended amount, after a mixing error. She had no symptoms when assessed and was managed with home monitoring and outpatient follow-up; no test results or longer-term outcome were reported. One uneventful case cannot show that injections are safe. [145]

Small, short studies can miss uncommon problems and problems that take months to appear. Only the 1994 wound-gel trial collected blood tests (blood counts, liver and kidney tests and blood copper), and it did not publish the results. So "no problems reported" often means "not looked for" or "not shown". [31], [10]

What side effects have been reported?

• On the skin. One woman in the facial wrinkle study withdrew after a mild reaction on both sides of her face, where she was using the GHK-Cu serum on one side and a Matrixyl 3000 comparison product on the other, so either could have caused it. The eyebrow study reported no allergic or serious reactions. In the 1994 ulcer trial, overall side-effect rates were similar with and without the gel. [27], [30], [31]
• After injection. Community accounts describe injection-site reactions far more than anything else: a painless injection followed, minutes to hours later, by burning or a deep ache that can last most of a day, plus redness, welts, itching, bruising, lumps and occasionally a blue tint at the site. Some people adapt within weeks; others stop. [46], [74], [60], [100]
• Whole-body symptoms. A few public accounts describe dizziness with a racing heart, headaches and muscle aches, or frightening thoughts and a feeling of unreality after injections. These reports cannot show that GHK-Cu caused the symptoms or how often they happen. [58], [101], [102], [59]

In June 2026 Australia's regulator reported liver damage and severe allergic reactions requiring hospital care among people using unapproved peptides, naming GHK-Cu among the products on sale. It did not link those cases to GHK-Cu specifically. [103]

Could it cause an allergic reaction?

It is possible, and it is the specific risk FDA names. FDA says that "compounded injectable drugs containing GHK-Cu may pose risk for immunogenicity due to the potential for aggregation and peptide-related impurities". [9]

In a public forum, one person described red, raised, itchy patches that lasted days after injections and wondered whether they were a delayed allergy. [74] Community education groups describe several possible hypersensitivity reactions: hives appearing at earlier injection sites minutes after a dose, welts that stopped after switching to a copper-free version of a blend, and a person with a known reaction to copper jewellery who could not tolerate GHK-Cu. Spreading hives, swelling of the face or throat, or trouble breathing need urgent medical care.

What about the copper?

Each 2 mg of GHK-Cu contains about 0.32 mg of copper. For comparison, adults need about 0.9 mg of copper a day from food, and the upper safe limit for copper from food and supplements is 10 mg a day, set to prevent liver damage. That limit applies to copper swallowed, not injected, so it cannot serve as an injection limit. [4], [88]

No study has measured blood copper after GHK-Cu injections. In community education groups, one person reported a high copper result with low zinc after a month at 2 mg a day, but the cause is unknown. Some people add oral copper or copper-containing supplements on top of injections, which increases total intake. People with Wilson disease, an inherited condition in which copper builds up in the liver and brain, are at high risk from excess copper. [88]

Zinc is often suggested alongside GHK-Cu. High-dose zinc supplements can themselves cause copper deficiency, which is one reason the adult upper limit for zinc is 40 mg a day. [88]

Could product quality change the risk?

Yes. The peptide's effects and the quality of a particular vial are separate questions. Injectable GHK-Cu products were recalled in 2020 and 2025, in FDA's Class II category, because sterility could not be assured. A GHK-Cu and BPC-157 powder was recalled in Canada in May 2026 because it was an unauthorized active pharmaceutical ingredient. The cosmetic safety review cites an older report that commercial GHK, the peptide without copper, was only about 95% pure. A "research use only" label says nothing about purity or sterility. [104], [82], [105], [8]

Is GHK-Cu legal? Is it FDA-approved?

Checked September 23, 2026. Rules differ by country and change quickly.

United States. GHK-Cu is not an FDA-approved drug. The developer's Iamin wound dressings were cleared in 1996 and 1997 as medical devices, which is not drug approval. The recent steps: [86], [106]

• 2023. FDA placed non-injectable GHK-Cu in the group of ingredients under evaluation for pharmacy compounding, and injectable GHK-Cu in the group raising significant safety concerns. [107]
• April and May 2026. After the nominations were withdrawn, FDA removed GHK-Cu from the evaluation list on April 22. On May 5 the nominator clarified that it had withdrawn only the injectable form, so non-injectable GHK-Cu returned to the list. FDA's safety-risk page now lists injectable GHK-Cu among withdrawn nominations and keeps its immune-reaction concern. [107], [9]
• Next. FDA's pharmacy compounding advisory committee will discuss GHK-Cu at a meeting before the end of February 2027; no date had been set. A committee vote is advice, not a final decision. [108]

Canada. Health Canada has not authorized GHK-Cu as a drug. Its 2025 and April 2026 warnings list GHK-Cu among seized, unauthorized injectable peptides, and copper tripeptide-1 appears in its natural health product ingredient database only as a non-medicinal skin-conditioning ingredient. [109], [110], [111]

Australia. The TGA names GHK-Cu among unapproved peptide products. In low-risk listed medicines, copper tripeptide-1 may be used only as an inactive ingredient (excipient) in products applied to the skin, at no more than 3%. That rule covers listed medicines, not cosmetics. [103], [112], [113]

New Zealand. Medsafe has proposed making injectable GHK-Cu a prescription medicine after intercepting it at the border. The committee meets on 28 October 2026; this is a proposal, not yet a decision. [114]

Colombia. INVIMA, the national medicines regulator, issued alerts in June and August 2026 naming GHK-Cu products sold without a sanitary registration. It classes such products as fraudulent: they cannot legally be sold in Colombia, and their quality, safety and efficacy have not been evaluated. [146]

A "research use only" label does not make a product legal to sell for human use.

Is GHK-Cu banned in sport?

It is not named on the World Anti-Doping Agency's 2026 or 2027 lists. That does not mean it is permitted: category S0 bans substances not approved for human therapeutic use, and the 2027 wording lists "peptides" among its examples. USADA lists plain GHK (tripeptide-1) as a cosmetic ingredient that is not prohibited, but that statement does not address injected copper GHK. Athletes should check with their anti-doping organization before using it in any form. [115], [116], [117]

Does GHK-Cu cause cancer?

Nobody knows. There are no human data either way and no long-term animal cancer studies. The early experiments point both ways: GHK helped some tumor-derived cells grow in a dish and copper-bound GHK triggered blood-vessel growth in rabbits, while a mouse tumor study combining GHK-Cu with vitamin C reported smaller tumors, without a GHK-Cu-only comparison. Neither direction is established in people. [1], [92], [118]

Who should be especially cautious?

These groups have no safety data in people. That is a reason for caution, not proof of harm.

• Pregnancy and breastfeeding. No human or reproductive studies exist for injected or high-strength topical GHK-Cu.
• Wilson disease or other copper-handling conditions. These conditions make copper toxicity more likely. [88]
• A history of cancer. Because of the unresolved findings above: new blood-vessel growth in rabbit eyes and tumor-cell growth in a dish. These are laboratory signals, not a shown risk in people. [92], [118]
• A history of allergic reactions, including to copper jewellery or to other injected peptides.
• Under 18. No studies include young people. This guide is written for adults.
• Competitive athletes. Category S0 may apply even though GHK-Cu is not named. [116]
• People taking other medicines or supplements. See the next question.

Has GHK-Cu been tested alongside other medicines?

Not in people. No study reports how injected GHK-Cu interacts with prescription medicines, and the skin studies did not test combinations with retinoids or acids. Websites warn against mixing it with vitamin C, acids or retinol in skin routines, but those warnings rest on chemistry reasoning, not on tests in people. Copper and zinc supplements, and medicines for Wilson disease, affect copper balance and are worth mentioning. Bring a complete list of everything you take to a pharmacist or doctor. [88], [75]

What should be monitored while using GHK-Cu?

There is no official monitoring plan, because no regulator has approved GHK-Cu as a medicine or written a label for it. Only one human study collected blood tests, and it did not publish the results. What follows is what the studies measured, plus the copper-related tests that general medical sources describe. It can help you prepare questions for a clinician; it is not a personal testing plan. [10], [88]

What did the human studies check?

• Skin and wound results only. The trials measured wound size and infection, wrinkles from images, skin samples, hair counts and local reactions. [31], [27], [30]
• Patch testing before use. The eyebrow study tested each participant's skin for a reaction before starting and excluded anyone who reacted. [30]
• Blood tests collected but not reported. The 1994 wound-gel trial took blood counts, liver and kidney tests and blood copper before and during treatment but did not publish the results. No human study we found reported ceruloplasmin (the main copper-carrying protein in blood), zinc or antibodies, and none checked blood tests after injections. [31], [10]

Which signals matter, and why?

These are reasons researchers and clinicians give for checking copper in general, not findings from GHK-Cu users. Discuss with a clinician whether any test makes sense for you. [88], [9]

What do people in public communities report?

Public discussions and community education groups describe glowing skin and thicker hair, no change after many months, and injection-site pain that made people stop. The most useful accounts say what else changed and come back with an update. [28], [29], [46]

What do the positive reports look like?

Most positive reports are about skin: a smoother texture, less redness, softer fine lines or compliments from others, usually noticed within the first one to two months of daily injections. One person described clearer, less red facial skin after three months of 2 mg a day, while noting that the photos were taken in different lighting and that weight-loss medicine and summer sun were part of the same period. [28], [119]

Older users often describe thin, fragile skin becoming sturdier. Two people in their sixties reported that the skin on their arms bruised and tore far less; one had also used the GLOW blend and BPC-157 with TB-500. Hair reports include faster growth and fuller hair after three or four months, usually alongside finasteride or other peptides. [29], [120], [121]

How long did those changes last?

The follow-up often changes the story. In one account, facial redness began to return during a month off. Another person found that red, dry skin returned about three weeks after finishing a blend. Community education groups describe skin changes at around 2–8 weeks, fine lines at 2–4 months and hair at 3–6 months, but those are impressions, not measured averages. [28], [61]

Does everyone describe an improvement?

No. Several people describe little or nothing: one after repeated 12-week courses over more than a year at 3 mg a day, another after seven months, another after almost three months of injections plus a skin product. A person with psoriasis found that raising the dose from 2 mg to 5 mg a day made no clear difference. [29], [61], [120], [47]

What about injection-site pain?

It is the most discussed experience. People describe a painless injection followed by burning or a deep ache that starts minutes to hours later and can last most of a day. One person had more than 15 hours of intense pain at 2 mg, and no pain at 1 mg with more dilution, warming and a different site, changes made all at once. Others describe welts lasting days, or lumps after repeated injections in the same spot. [46], [74], [100]

Some people adapt after a few weeks; others never do. In community education groups, two people using the same vial often reacted very differently. The reported fixes (more dilution, deeper injection, the upper buttock, zinc, antihistamines) have not been tested, and some carry their own risks.

Do "copper uglies" mean it is working?

The reviewed accounts do not support that conclusion. "Copper uglies" describes skin that seems to look worse, with new lines, sagging, dryness or breakouts, after starting a copper peptide. It comes up mostly with topical products. One person saw new forehead lines after ten days of a serum, and they partly faded within days of stopping. No study has described or measured this effect, and calling it a necessary "remodeling phase" adds an explanation the accounts cannot establish. [122], [123], [124]

What about other unwanted effects?

A few accounts describe dizziness with a racing heart, headaches and aches, or frightening thoughts and a feeling of unreality after injections, sometimes lasting days. One person who accidentally took ten times the intended amount for two months said they felt fine and saw no benefit. These are single reports that cannot establish cause or frequency. [58], [101], [59], [125]

How can you judge a GHK-Cu story?

Useful questions to ask: What exactly was used, GHK-Cu alone or a blend, and how much? Was it a skin product or an injection? What else changed: weight, retinoids, minoxidil, sun, other peptides? Were the photos taken in the same light? What happened weeks later, and after stopping?

These selected discussions help identify experiences that research should examine. They are not a survey of all users, a response rate or a substitute for controlled studies.

How does GHK-Cu compare with BPC-157, TB-500 and KPV?

These three peptides are GHK-Cu's partners in the GLOW and KLOW blends, and they are sold by the same suppliers. The table compares what each one is and how much human evidence exists. The route and schedule column describes what protocol sources say, not tested doses.

The real differences are in identity and evidence, not in proven results. GHK-Cu's human studies almost all used skin products and wound gels; BPC-157 has a few small human studies by other routes; TB-500 and KPV have none. No study has compared these peptides with each other, or tested their blends, in people, so the table cannot say which works better for any problem. [10], [128], [130]

Common questions about GHK-Cu

How long does GHK-Cu take to work?

There is no reliable answer. In the skin studies, measurements were taken after 8–12 weeks, and where effects were found they were small. Community accounts describe skin changes within one to two months and hair changes after three to six months, but also many reports of no change at all after long courses. [27], [30], [29] See what people reported over time.

Is injectable GHK-Cu the same as the copper peptide in my serum?

The main ingredient is the same kind of molecule, but the product and the exposure are not. Serums hold GHK-Cu (or sometimes a different copper peptide) in a cream or liquid at around 1–2%, and only a small fraction crosses the skin. Injectable vials are powders meant to be mixed and injected, and we found no tests of them in people. Some products labeled "copper peptides" also contain palmitoyl tripeptide-1, which has no copper. [64], [132], [7] See why the route matters.

Is a cream or an injection better?

Nobody has compared them. Almost all the human evidence comes from creams, gels and serums, while subcutaneous injections have only website protocols and personal accounts behind them. An injection exposes the body to the peptide, its copper and any impurities in a way a cream does not, which is why FDA's safety concern applies to injectable forms. Some people in community discussions switched to a topical product after injection-site reactions. [10], [9], [60]

Should you take zinc with GHK-Cu?

There is no study of zinc alongside GHK-Cu. Zinc is suggested online to balance copper or to reduce stinging, but those ideas have not been tested, and doses in community discussions range widely. High-dose zinc supplements can cause copper deficiency on their own, and the adult upper limit for zinc is 40 mg a day. If you are thinking about zinc or copper supplements, a clinician can help decide whether any test makes sense. [88], [124], [100], [52]

Does a blue color mean a vial is genuine?

No. GHK-Cu is blue because of its copper, but copper salts are blue too, and in the developer's own patent a solution stayed deep blue while it formed a heavy sediment. Color cannot confirm identity, strength or sterility. The injectable GHK-Cu recalls in FDA's records were for sterility problems that color would never reveal. [81], [82]

Does GHK-Cu regrow hair?

It has not been shown to. The only controlled human study found slightly more eyebrow hairs with a 2% serum after 12 weeks. No controlled study has tested GHK-Cu alone for scalp hair loss, and the laboratory hair-follicle study often cited used a different copper peptide, AHK-Cu. Hair stories online usually involve finasteride or other peptides at the same time. [30], [7], [121]

Is it legal to buy GHK-Cu?

Skin-care products containing copper tripeptide-1 are widely sold. [70], [132] Injectable GHK-Cu is not an approved medicine in the United States, Canada or Australia, and New Zealand is considering making it prescription-only. A "research use only" label does not make a product legal or safe to inject. See the dated legal-status summary. [107], [109], [113], [114]

Glossary

Plain explanations of the route, dosing and research terms used in this guide. Underlined terms in the text link here.

Adverse event

A harmful or unwanted medical event reported after someone used a treatment. A report alone does not prove the treatment caused it.

Aggregation

Peptide molecules clumping together. Clumps can make a product weaker and, when injected, more likely to trigger an immune reaction.

Amino acid

A small chemical building block. Chains of amino acids make up peptides and proteins.

Angiogenesis

The growth of new blood vessels from existing ones. It is a normal part of healing, and researchers also study it closely in cancer.

Animal study

Research in animals such as rats or mice. It shows what a substance does in a living body, but results in people can differ.

Bioavailability

How much of a dose reaches the bloodstream in a usable form. It depends heavily on the route. It has not been measured for GHK-Cu.

Blend

A product that combines GHK-Cu with other peptides, such as GLOW or KLOW. The blend's total amount is not its GHK-Cu amount.

BPC-157

A lab-made chain of 15 amino acids discussed for injury recovery. It is one of the partner peptides in the GLOW and KLOW blends.

Cell study (in vitro)

Research on cells grown in a dish. It gives early clues about biology, but it is far from proof of benefit in people.

Ceruloplasmin

The main protein that carries copper in the blood. Its level is used, with blood copper, to investigate copper disorders.

Collagen

The main structural protein in skin, tendons and other connective tissue. It gives skin its firmness.

Compounding

When a pharmacy prepares a customized medicine from individual ingredients. In the US, federal lists control which bulk ingredients pharmacies may use.

Controlled trial

A study that compares people who receive a treatment with a similar group who do not, often receiving a placebo instead. Randomly assigning people to each group makes the comparison fairer.

Copper tripeptide-1

The ingredient-label name for GHK-Cu in skin-care products.

Course and cycle

A course is the period of repeated use, such as 30 days. A cycle is a course plus a planned break before any further use.

Daily total

All the amounts given in one day, added together. For example, 1 mg twice daily is a 2 mg daily total.

Excipient

An inactive ingredient in a medicine, such as a thickener or preservative, as opposed to the active ingredient.

Fibroblast

A cell that builds and maintains connective tissue, such as the supporting layer of skin, mainly by making collagen.

Freeze-dried (lyophilized)

Dried by freezing and removing the water, leaving a powder. Injectable GHK-Cu is usually sold this way and mixed with liquid before use.

Half-life

The time it takes for the measured level of a substance in the blood to fall by half. It is not the same as how long an effect lasts.

Hypersensitivity reaction

An allergic-type reaction by the immune system, ranging from itchy welts to swelling and trouble breathing.

Immunogenicity

The ability of a substance to trigger an immune response, such as an allergic reaction or antibodies against it.

Intradermal

Injected into the skin itself rather than under it, as in some cosmetic procedures.

Intramuscular (IM)

Injected into a muscle.

Intravenous (IV)

Given directly into a vein, so it enters the bloodstream immediately.

Investigational

Still being studied and not approved by a regulator, such as the FDA, to treat any condition.

KPV

A lab-made three-amino-acid fragment of a hormone called α-MSH. It is the extra ingredient that turns GLOW into KLOW.

Matrix metalloproteinases (MMPs)

Enzymes that break down collagen and other supporting tissue, clearing damaged tissue so it can be rebuilt.

mcg and mg

Micrograms and milligrams. 1 mg equals 1,000 mcg. GHK-Cu injection amounts are usually written in mg.

Peptide

A short chain of amino acids. GHK is a chain of three.

Pharmacokinetics

How the body absorbs, moves, breaks down and removes a substance. It has not been studied for GHK-Cu in people.

Placebo

A dummy treatment with no active ingredient, such as an inactive gel, used as a comparison in studies.

Preclinical research

Studies done before research in people: cell studies and animal studies.

Reconstitution

Mixing a freeze-dried powder with a liquid so it can be measured and injected. The amount of liquid sets how much peptide each unit holds.

Research use only

A label on products sold for laboratory research. It does not mean a product is approved, tested for human use or legal to sell as a medicine.

Subcutaneous (SC)

Injected into the fatty layer just under the skin. This is the route most GHK-Cu protocol descriptions use.

Syringe units

Markings on an insulin syringe that measure volume. On a U-100 syringe, 100 units equal 1 mL. The amount of drug per unit depends on the vial's concentration.

TB-500

A lab-made peptide sold as a relative of thymosin beta-4, a protein the body makes. It is one of the partner peptides in GLOW and KLOW.

Titration

Adjusting a dose in steps, usually starting lower and increasing if needed.

Topical

Applied to the skin, as a cream, gel or serum.

WADA

The World Anti-Doping Agency, which publishes the list of substances banned in sport.

Withdrawal and rebound

Withdrawal effects are symptoms caused by stopping a substance. A rebound is a problem returning worse than before after stopping. Neither has been studied for GHK-Cu.

Supporting research: animal and cell studies

How this guide was researched

This guide is built from a thorough review of the sources cited throughout it: published scientific studies, registered clinical-trial plans, regulatory documents and published protocol descriptions. We also reviewed public online forums and community education groups where people describe their own experiences with GHK-Cu.

The guide cites 146 sources, including 44 original scientific papers (8 human studies and 36 cell, animal and laboratory studies). Each type of source answers a different question. Studies show what researchers measured. Protocol descriptions show how GHK-Cu is typically used. Personal accounts show what individual people experienced. Every numbered citation links to its entry below, labeled by source type.

How this guide was made

Research and drafting were AI-assisted. Every cited source was checked against the original, and the guide was reviewed and edited by Doserly before publication. It has not had an independent clinical review, and Doserly does not currently have medical reviewers. Doserly makes a medication and health-tracking app and runs Doserly Academy, both of which are promoted in this guide. Read our editorial policy for how guides are researched, updated and corrected.

This guide is for educational purposes. It summarizes what the reviewed sources report so the research is easier to understand; it is not medical advice. For a deeper dive, or to check any point for yourself, go straight to the cited sources.

Explore the sources